CP-25 exhibits therapeutic efficacy against kidney injury in DKD. Its primary mechanism involves modulating the differentiation and function of DCs, which affects the activation of T cells. In terms of mechanism, CP-25 targets the GRK2-mediated JAK2-STAT3-SOCS3 signalling pathway to inhibit inflammation for alleviating DKD.
Liang et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: